Clinical outcomes of neoadjuvant chemotherapy for patients with breast cancer: Tri-weekly nanoparticle albumin-bound paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide: a retrospective observational study.

1. Gralow JR, Burstein HJ, Wood W, et al. Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease. J Clin Oncol. 2008;26(5):814–819. doi: 10.1200/

jco.2007.15.3510.

2. Kitajima K, Miyoshi Y, Yamano T, Odawara S, Higuchi T, Yamakado K. Assessment of tumor response

to neoadjuvant chemotherapy in patients with breast cancer using MRI and FDG-PET/CT-RECIST 1.1 vs.

PERCIST 1.0. Nagoya J Med Sci. 2018;80(2):183–197. doi: 10.18999/nagjms.80.2.183.

3. Earl HM, Vallier AL, Hiller L, et al. Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk

early breast cancer (Neo-tAnGo): an open-label, 2x2 factorial randomised phase 3 trial. Lancet Oncol.

2014;15(2):201–212. doi: 10.1016/s1470-2045(13)70554-0.

4. von Minckwitz G, Rezai M, Loibl S, et al. Capecitabine in addition to anthracycline- and taxane-based

neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro Study. J Clin Oncol.

2010;28(12):2015–2023. doi: 10.1200/jco.2009.23.8303.

5. Ibrahim NK, Desai N, Legha S, et al. Phase I and pharmacokinetic study of ABI-007, a cremophor-free,

protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res. 2002;8(5):1038–1044.

6. Gardner ER, Dahut WL, Scripture CD, et al. Randomized crossover pharmacokinetic study of solvent-based

paclitaxel and nab-paclitaxel. Clin Cancer Res. 2008;14(13):4200–4205. doi: 10.1158/1078-0432.ccr-07-4592.

7. Madappa N Kundranda JN. Albumin-bound paclitaxel in solid tumors: clinical development and future

directions. Drug Des Devel Ther. 2015;9:3767–3777.

8. Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol.

2005;23(31):7794–7803. doi: 10.1200/jco.2005.04.937.

466

Masato Shizuku et al

9. Robidoux A, Buzdar AU, Quinaux E, et al. A phase II neoadjuvant trial of sequential nanoparticle albuminbound paclitaxel followed by 5-fluorouracil/epirubicin/cyclophosphamide in locally advanced breast cancer.

Clin Breast Cancer. 2010;10(1):81–86. doi: 10.3816/CBC.2010.n.011.

10. Shimada H, Ueda S, Saeki T, et al. Neoadjuvant triweekly nanoparticle albumin-bound paclitaxel followed

by epirubicin and cyclophosphamide for Stage II/III HER2-negative breast cancer: evaluation of efficacy

and safety. Jpn J Clin Oncol. 2015;45(7):642–649. doi: 10.1093/jjco/hyv055.

11. Untch M, Jackisch C, Schneeweiss A. Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant

chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial. Lancet Oncol.

2016;17(7):E270-E270.

12. Tanaka S, Iwamoto M, Kimura K, et al. Phase II study of neoadjuvant anthracycline-based regimens

combined with nanoparticle albumin-bound paclitaxel and trastuzumab for human epidermal growth factor receptor 2-positive operable breast cancer. Clin Breast Cancer. 2015;15(3):191–196. doi: 10.1016/j.

clbc.2014.12.003.

13. Network NCC. Clinical Practice Guidelines in Oncology. Breast Cancer Version 3. 2019. https://www.nccn.

org/professionals/physician_gls/default.aspx. Published September 6, 2019. Accessed February 4, 2020.

14. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised

RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–247. doi: 10.1016/j.ejca.2008.10.026.

15. Cancer Therapy Evaluation Program (CTEP). Common terminology criteria for adverse events (CTCAE)

v4.0. https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm. Accessed February 4, 2020.

16. Morita S, Kikumori T, Tsunoda N, et al. Feasibility of dose-dense epirubicin and cyclophosphamide with

subcutaneous pegfilgrastim 3.6 mg support: a single-center prospective study in Japan. Int J Clin Oncol.

2018;23(1):195–200. doi: 10.1007/s10147-017-1177-z.

17. Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow

Transplant. 2013;48(3):452–458. doi: 10.1038/bmt.2012.244.

18. Rowinsky EK, Donehower RC. Paclitaxel (taxol). N Engl J Med. 1995;332(15):1004–1014. doi: 10.1056/

nejm199504133321507.

19. Wani MC, Taylor HL, Wall ME, Coggon P, McPhail AT. Plant antitumor agents .6. Isolation and

structure of taxol, a novel antileukemic and antitumor agent from Taxus-Brevifolia. J Am Chem Soc.

1971;93(9):2325–2327. doi: 10.1021/ja00738a045.

20. Loibl S, de la Pena L, Nekljudova V, et al. Neoadjuvant buparlisib plus trastuzumab and paclitaxel for

women with HER2+primary breast cancer: a randomised, double-blind, placebo-controlled phase II trial

(NeoPHOEBE). Eur J Cancer. 2017;85:133–145. doi: 10.1016/j.ejca.2017.08.020

21. Untch M, Fasching PA, Konecny GE, et al. Pathologic complete response after neoadjuvant chemotherapy

plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups. J Clin Oncol.

2011;29(25):3351–3357. doi: 10.1200/jco.2010.31.4930

22. Zhang P, Yin Y, Mo HN, et al. Better pathologic complete response and relapse-free survival after carboplatin plus paclitaxel compared with epirubicin plus paclitaxel as neoadjuvant chemotherapy for locally

advanced triple-negative breast cancer: a randomized phase 2 trial. Oncotarget. 2016;7(37):60647–60656.

doi: 10.18632/oncotarget.10607.

23. Futamura M, Nagao Y, Ishihara K, et al. Preoperative neoadjuvant chemotherapy using nanoparticle albuminbound paclitaxel followed by epirubicin and cyclophosphamide for operable breast cancer: a multicenter

phase II trial. Breast Cancer. 2017;24(4):615–623. doi: 10.1007/s12282-016-0748-6.

24. Kojima Y, Kawamoto H, Nishikawa T, et al. Feasibility study of weekly nanoparticle albumin-bound

paclitaxel (150 mg/m(2)) followed by fluorouracil, epirubicin, and cyclophosphamide therapy as neoadjuvant

chemotherapy for HER2-negative breast cancer. Clin Breast Cancer. 2018;18(5):374–379. doi: 10.1016/j.

clbc.2018.01.002.

25. Shigematsu H, Kadoya T, Masumoto N, et al. The efficacy and safety of preoperative chemotherapy with

triweekly abraxane and cyclophosphamide followed by 5-fluorouracil, epirubicin, and cyclophosphamide

therapy for resectable breast cancer: a multicenter clinical trial. Clin Breast Cancer. 2015;15(2):110–116.

doi: 10.1016/j.clbc.2014.09.010.

26. Cheang MCU, Chia SK, Voduc D, et al. Ki67 index, HER2 status, and prognosis of patients with luminal

B breast cancer. J Natl Cancer Inst. 2009;101(10):736–750. doi: 10.1093/jnci/djp082.

27. Tokuda E, Horimoto Y, Arakawa A, et al. Differences in Ki67 expressions between pre- and post-neoadjuvant

chemotherapy specimens might predict early recurrence of breast cancer. Hum Pathol. 2017;63:40–45. doi:

10.1016/j.humpath.2017.02.005.

28. Untch M, Jackisch C, Schneeweiss A, et al. Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant

467

Nab-PTX/FEC as neoadjuvant chemotherapy

29. 30. 31. 32. chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial. Lancet Oncol.

2016;17(3):345–356. doi: 10.1016/s1470-2045(15)00542-2.

Earl HM, Hiller L, Dunn JA, et al. Efficacy of neoadjuvant bevacizumab added to docetaxel followed

by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer

(ARTemis): an open-label, randomised, phase 3 trial. Lancet Oncol. 2015;16(6):656–666. doi: 10.1016/

s1470-2045(15)70137-3.

Foldi J, Mougalian S, Silber A, et al. Single-arm, neoadjuvant, phase II trial of pertuzumab and trastuzumab

administered concomitantly with weekly paclitaxel followed by 5-fluoruracil, epirubicin, and cyclophosphamide (FEC) for stage I-III HER2-positive breast cancer. Breast Cancer Res Treat. 2018;169(2):333–340.

doi: 10.1007/s10549-017-4653-2.

Bonadonna G, Valagussa P, Moliterni A, Zambetti M, Brambilla C. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med.

1995;332(14):901–906. doi: 10.1056/nejm199504063321401

Raza S, Welch S, Younus J. Relative dose intensity delivered to patients with early breast cancer: Canadian

experience. Curr Oncol. 2009;16(6):393–397. doi. 10.3747/co.v16i6.311.

...